Status:
COMPLETED
Ivermectin as a Novel Therapy in COVID-19 Treatment
Lead Sponsor:
Tanta University
Conditions:
COVID
Eligibility:
All Genders
Phase:
PHASE2
PHASE3
Brief Summary
Efficacy of Ivermectin in COVID-19 treatment
Detailed Description
Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 treatment
Eligibility Criteria
Inclusion
- All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR.
Exclusion
- Allergy or contraindication to the drugs used in the study.
- Pregnant and lactating mothers.
- Patients with cardiac problems.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT04403555
Start Date
June 1 2020
End Date
December 1 2020
Last Update
August 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sherief Abd-Elsalam
Tanta, Egypt